October 2024 – Page 18 – Talk Bio

Actionable Insights Powered by AI

B. Braun’s Florida IV Fluid Plant Resumes Operations After Minimal Damage from Hurricane Milton

7 months ago talkbio0Tagged B. Braun, Florida Facility, Hurricanes, Liquid substance, Milton

B. Braun, Hurricane Milton, IV Fluids, Florida Facility, Supply Chain

Pfizer Secures EU Approval for TALZENNA in Combination with XTANDI for Metastatic Castration-Resistant Prostate Cancer

7 months ago talkbio0Tagged Commission approval, European (ethnic group), Inhibitor, Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, PARP1 gene, Talzenna, Xtandi

TALZENNA, XTANDI, metastatic castration-resistant prostate cancer (mCRPC), PARP inhibitor, European Commission approval, prostate cancer treatment.

Leo Pharma Announces Major Restructuring with Up to 250 Layoffs and Relocations

7 months ago talkbio0Tagged Biopharma, Pharma, Relocations, restructuring

Leo Pharma, layoffs, relocations, restructuring, biopharma, job cuts

FDA Delays Approval of Zealand Pharma’s Dasiglucagon for Congenital Hyperinsulinism Due to Third-Party Manufacturing Issues

7 months ago talkbio0Tagged Complete, Congenital MeSH qualifier, dasiglucagon, Hyperinsulinism, issues, Response process, Third, third-party, United States Food and Drug Administration, Zealand Pharma

Zealand Pharma, dasiglucagon, congenital hyperinsulinism, FDA, Complete Response Letter, third-party manufacturing issues

Astellas Reduces Universal Cells Workforce in Seattle, Relocates 12 Positions to Japan

7 months ago talkbio0Tagged Astellas, Cell Therapy, Japan, Seattle, Universal Cells

Astellas, Universal Cells, layoffs, Seattle, Japan, cell therapy, biotech

Eli Lilly and insitro Collaborate on AI-Driven Metabolic Disease Therapies

7 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Biotechnology, Drug Discovery, Eli, Eli Lilly, GalNAc, Insitro, Metabolic Diseases, pharmaceutical partnership, RNA, Small Interfering

Eli Lilly, insitro, AI, metabolic diseases, siRNA, GalNAc, drug discovery, biotechnology, pharmaceutical partnership

Vanqua Bio Advances Experimental Parkinson’s Therapy with VQ-101, Bolsters Leadership Team

7 months ago talkbio0Tagged Accumulation, alpha-Synuclein, Bio, Clinical Trials, GBA gene, GCase, GCase activator, Lysosomal dysfunction, Neurodegenerative Disorders, Parkinson 's disease, Vanqua, VQ-101

Vanqua Bio, VQ-101, Parkinson’s disease, GBA gene mutations, GCase activator, Neurodegenerative diseases, Clinical trials, Lysosomal dysfunction, Alpha-synuclein accumulation

Basecamp Research Secures $60M to Revolutionize AI Drug Discovery with Broad Institute Partnership

7 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial (qualifier value), biology (field), Biotechnology, Broad Institute, gene therapy, IMMUNODEFICIENCY, COMMON VARIABLE, 10, R. Liu, research

AI drug discovery, Basecamp Research, Broad Institute, David R. Liu, Biotechnology, Gene therapy, Artificial intelligence in biology

Arda Therapeutics Secures $43M Series A Funding to Pioneer ADCs for Fibrotic Diseases

7 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Arda, Eli, Eli Lilly, fibrotic diseases, Funding, Horowitz, Immunostimulating conjugate (antigen), Series

Arda Therapeutics, Series A Funding, Fibrotic Diseases, Antibody-Drug Conjugates (ADCs), Eli Lilly, Andreessen Horowitz (a16z)

Purespring Therapeutics Secures £80M ($105M) Series B Funding to Advance IgAN Gene Therapy into Clinical Trials

7 months ago talkbio0Tagged AAVS1 gene, Clinical Trials, gene therapy, glomerular kidney disease, IGA Glomerulonephritis, Kidney Diseases, Nephrotic Syndrome, Podocytes, Purespring, Series B

Purespring Therapeutics, IgAN gene therapy, kidney disease, Series B funding, clinical trials, AAV gene therapy, podocytes, nephrotic syndrome, glomerular kidney disease.